Vi­a­tris agrees to pay $264M to set­tle EpiPen class ac­tion case

4 years ago
Pharma
Law

As Eli Lil­ly steams ahead with a close­ly-watched BTK drug, its ri­vals at Mer­ck are tak­ing a $275M write-down on de­lay

4 years ago
R&D

Phar­mas ral­ly to pro­tect em­ploy­ees in Ukraine, along with sup­port and do­na­tions to Rus­sia-in­vad­ed coun­try

4 years ago
Pharma
Marketing

Pfiz­er and Alvotech look to in­ter­change­abil­i­ty to stand out in a crowd­ed Hu­mi­ra biosim­i­lar field

4 years ago
Pharma

J&J grows in­vest­ment fund for en­tre­pre­neurs, sets 2022 fo­cus on health­care work­er gaps and racial in­equities

4 years ago
Pharma
Marketing

Emer­gen­t's trou­bled Bal­ti­more site gets $100M up­grade

4 years ago
Pharma
Manufacturing

Safe­ty con­cerns cause GSK to stop high­ly an­tic­i­pat­ed vac­cine tri­al in sur­prise set­back

4 years ago
R&D
Pharma

Ap­pili lands DOD mon­ey for bioter­ror­ism vac­cine; Goldfinch touts new PhII da­ta

4 years ago
News Briefing

An­oth­er burned-out SPAC biotech rais­es the white flag as CEO de­parts, strate­gic re­view be­gins

4 years ago
People
R&D

Hold the phone, bio­phar­ma: FDA-im­posed clin­i­cal holds are on the rise

4 years ago
Cell/Gene Tx
FDA+

Af­ter be­ing ush­ered on­to the in­side lane at FDA, reg­u­la­tors hand Am­ryt a CRL for rare dis­ease drug

4 years ago
FDA+

Blue­print part­ners up with a de­grad­er-fo­cused 'van­t' as part of pipeline-boost­ing cam­paign

4 years ago
Deals

De­vel­op­ers of a key mR­NA de­liv­ery tech, seek­ing a piece of Mod­er­na's Covid rich­es, sue for patent in­fringe­ment

4 years ago
Pharma
Law

FDA re­jects Reata's kid­ney drug af­ter ad­comm vot­ed unan­i­mous­ly against it

4 years ago
Pharma
FDA+

In lat­est set­back for sol­id tu­mor CAR-T, Celyad paus­es tri­al fol­low­ing two pa­tient deaths

4 years ago
R&D
Cell/Gene Tx

In all-en­com­pass­ing rights deal with Huadong, Di­et­mar Hop­p's Hei­del­berg looks to bring its AD­Cs to most of Asia

4 years ago
Deals

Biosim­i­lars unite: Look­ing for com­mer­cial con­sol­i­da­tion, Bio­con buys out long­time part­ner Vi­a­tris for $3.3B

4 years ago
Deals

Lat­est news on J&J's ma­jor court win; Ukraine's place in biotech; Man­ag­ing ex­pec­ta­tions for AI; Lil­ly ups its RNA ...

4 years ago
Weekly

US judge rules in fa­vor of J&J in con­tro­ver­sial 'Texas two-step' case

4 years ago
Pharma

EMA short­ens time­line for Mod­er­na's Spike­vax Covid boost­er 

4 years ago
Pharma
Coronavirus

Bio­haven con­tin­ues push for oral mi­graine med Nurtec amid new port­fo­lio line up

4 years ago
Pharma
Marketing

FTC wants to know: How are PBMs af­fect­ing drug af­ford­abil­i­ty and ac­cess?

4 years ago
Pharma

J&J, drug dis­trib­u­tors sign off on a mam­moth $26B opi­oid set­tle­ment with 46 states

4 years ago
Pharma

Glax­o­SmithK­line am­pli­fies the agony of ‘la cule­bril­la’ to raise shin­gles aware­ness with Span­ish speak­ers

4 years ago
Pharma
Marketing
First page Previous page 567568569570571572573 Next page Last page
A service from the Financial Times